• Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar).
  
• Mutation; HGNC; 1787; CDKN2A; Simple; p.Gln50Ter (c.148C>T); ClinVar=VCV000220711; Zygosity=Unspecified (PubMed=23851445).
  
• Mutation; HGNC; 6342; KIT; Simple; p.Leu576Pro (c.1727T>C); ClinVar=VCV000375919; Zygosity=Unspecified (PubMed=23851445; PubMed=24576830; Wistar).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Cys242Gly (c.724T>G); ClinVar=VCV000376581; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
  

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=17260012; DOI=10.1038/sj.onc.1210252
Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 26:4738-4748(2007)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=22578220; DOI=10.1111/j.1755-148X.2012.01016.x
Furney S.J., Turajlic S., Fenwick K., Lambros M.B., Mackay A., Ricken G., Mitsopoulos C., Kozarewa I., Hakas J., Zvelebil M., Lord C.J., Ashworth A., Reis-Filho J.S., Herlyn M., Murata H., Marais R.
Genomic characterisation of acral melanoma cell lines.
Pigment Cell Melanoma Res. 25:488-492(2012)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014)